Caisse DE Depot ET Placement DU Quebec Takes Position in Inspire Medical Systems, Inc. (NYSE:INSP)

Caisse DE Depot ET Placement DU Quebec bought a new position in Inspire Medical Systems, Inc. (NYSE:INSP - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 3,983 shares of the company's stock, valued at approximately $738,000.

A number of other hedge funds also recently added to or reduced their stakes in INSP. First Horizon Advisors Inc. boosted its holdings in shares of Inspire Medical Systems by 885.7% in the fourth quarter. First Horizon Advisors Inc. now owns 138 shares of the company's stock valued at $26,000 after acquiring an additional 124 shares in the last quarter. Huntington National Bank boosted its stake in Inspire Medical Systems by 228.3% during the fourth quarter. Huntington National Bank now owns 174 shares of the company's stock valued at $32,000 after buying an additional 121 shares in the last quarter. Harbour Investments Inc. grew its holdings in Inspire Medical Systems by 101.0% during the fourth quarter. Harbour Investments Inc. now owns 197 shares of the company's stock worth $37,000 after acquiring an additional 99 shares during the period. AlphaQuest LLC grew its position in Inspire Medical Systems by 7,275.0% in the fourth quarter. AlphaQuest LLC now owns 295 shares of the company's stock worth $55,000 after buying an additional 291 shares during the last quarter. Finally, Quadrant Capital Group LLC lifted its holdings in shares of Inspire Medical Systems by 61.9% during the fourth quarter. Quadrant Capital Group LLC now owns 327 shares of the company's stock valued at $61,000 after purchasing an additional 125 shares during the last quarter. 94.91% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

INSP has been the topic of several research analyst reports. Stifel Nicolaus lowered their price objective on shares of Inspire Medical Systems from $190.00 to $175.00 and set a "hold" rating on the stock in a research report on Monday, April 21st. JPMorgan Chase & Co. reduced their price objective on Inspire Medical Systems from $235.00 to $195.00 and set an "overweight" rating for the company in a research note on Tuesday. KeyCorp reduced their price target on shares of Inspire Medical Systems from $234.00 to $216.00 and set an "overweight" rating for the company in a research report on Monday, April 21st. Royal Bank of Canada cut their target price on shares of Inspire Medical Systems from $260.00 to $215.00 and set an "outperform" rating for the company in a research report on Tuesday, April 15th. Finally, Wells Fargo & Company dropped their price target on shares of Inspire Medical Systems from $195.00 to $174.00 and set an "equal weight" rating on the stock in a research note on Tuesday. Three equities research analysts have rated the stock with a hold rating and eight have issued a buy rating to the company's stock. According to MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $211.91.

Inspire Medical Systems Stock Down 3.1 %

Shares of NYSE:INSP traded down $5.01 during midday trading on Wednesday, reaching $156.87. The company had a trading volume of 735,186 shares, compared to its average volume of 587,782. Inspire Medical Systems, Inc. has a 1-year low of $123.00 and a 1-year high of $225.00. The stock has a market cap of $4.67 billion, a PE ratio of 90.68, a P/E/G ratio of 2.86 and a beta of 1.39. The business's 50 day moving average price is $158.89 and its 200 day moving average price is $178.98.

Inspire Medical Systems (NYSE:INSP - Get Free Report) last released its quarterly earnings data on Monday, May 5th. The company reported $0.10 earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.33. Inspire Medical Systems had a net margin of 6.67% and a return on equity of 8.19%. The company had revenue of $201.32 million for the quarter, compared to analyst estimates of $194.89 million. During the same period in the previous year, the business earned ($0.34) EPS. Inspire Medical Systems's revenue for the quarter was up 22.7% compared to the same quarter last year. On average, research analysts expect that Inspire Medical Systems, Inc. will post 2.16 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Inspire Medical Systems news, insider Randy Ban sold 25,584 shares of the company's stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $183.50, for a total value of $4,694,664.00. Following the transaction, the insider now directly owns 7,259 shares of the company's stock, valued at $1,332,026.50. This represents a 77.90 % decrease in their position. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CTO John Rondoni sold 583 shares of the company's stock in a transaction dated Tuesday, February 11th. The shares were sold at an average price of $170.49, for a total transaction of $99,395.67. Following the completion of the transaction, the chief technology officer now owns 10,424 shares in the company, valued at $1,777,187.76. This trade represents a 5.30 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 26,527 shares of company stock valued at $4,851,660 over the last ninety days. 4.10% of the stock is currently owned by company insiders.

About Inspire Medical Systems

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.